Decitabine: a historical review of the development of an epigenetic drug

被引：43
作者：
de Vos, D [1 ]
van Overveld, W [1 ]
机构：
[1] Pharmachem BV, Haarlem, Netherlands
来源：
ANNALS OF HEMATOLOGY | 2005年 / 84卷 / Suppl 1期
关键词：
hypomethylation; MDS; AML; CML; stem cell; sickle cell;
D O I：
10.1007/s00277-005-0008-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.
引用
收藏
页码：3 / 8
页数：6
相关论文
共 51 条
[1]  
ABBRUZZESE J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P204
[2]   THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP EXPERIENCE WITH 5-AZA-2'-DEOXYCYTIDINE (NSC-127716) IN PATIENTS WITH COLO-RECTAL, HEAD AND NECK, RENAL CARCINOMAS AND MALIGNANT MELANOMAS [J].
ABELE, R ;
CLAVEL, M ;
DODION, P ;
BRUNTSCH, U ;
GUNDERSEN, S ;
SMYTH, J ;
RENARD, J ;
VANGLABBEKE, M ;
PINEDO, HM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (12) :1921-1924
[3]   Phase I trial of continuous infusion 5-aza-2′-deoxycytidine [J].
Aparicio, A ;
Eads, CA ;
Leong, LA ;
Laird, PW ;
Newman, EM ;
Synold, TW ;
Baker, SD ;
Zhao, M ;
Weber, JS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :231-239
[4]  
BOUCHARD J, 1983, MOL PHARMACOL, V24, P109
[5]   KINETICS OF DEAMINATION OF 5-AZA-2'-DEOXYCYTIDINE AND CYTOSINE-ARABINOSIDE BY HUMAN-LIVER CYTIDINE DEAMINASE AND ITS INHIBITION BY 3-DEAZAURIDINE, THYMIDINE OR URACIL ARABINOSIDE [J].
CHABOT, GG ;
BOUCHARD, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (07) :1327-1328
[6]  
Colly, 1990, HAEMATOLOGICA, V76, P43
[7]   PHENOTYPIC CONVERSION OF CULTURED MOUSE EMBRYO CELLS BY AZA PYRIMIDINE NUCLEOSIDES [J].
CONSTANTINIDES, PG ;
TAYLOR, SM ;
JONES, PA .
DEVELOPMENTAL BIOLOGY, 1978, 66 (01) :57-71
[8]   STRUCTURE OF 2'-DEOXY-5-AZACYTIDINE (DECITABINE) MONOHYDRATE [J].
DAVIES, MJ ;
JENKINS, PR ;
PROUSE, LJS ;
RUSSELL, DR ;
DEVOS, D .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1991, 47 :1418-1420
[9]   Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias [J].
de Lima, M ;
Ravandi, F ;
Shahjahan, M ;
Andersson, B ;
Couriel, D ;
Donato, M ;
Khouri, I ;
Gajewski, J ;
van Besien, K ;
Champlin, R ;
Giralt, S ;
Kantarjian, H .
CANCER, 2003, 97 (05) :1242-1247
[10]   Epigenetics in human disease and prospects for epigenetic therapy [J].
Egger, G ;
Liang, GN ;
Aparicio, A ;
Jones, PA .
NATURE, 2004, 429 (6990) :457-463
123456